Overview

Inorganic Nitrite to Amplify the Benefits and Tolerability of Exercise Training in Heart Failure With Preserved Ejection Fraction (HFpEF) (INABLE-Training)

Status:
Recruiting

Trial end date:
2022-03-01

Target enrollment:

Participant gender:

Summary

Participants with heart failure with preserved ejection fraction will undergo 12 weeks of cardiac rehabilitation for exercise training (ET) and be randomized to either oral sodium nitrite capsules or oral placebo capsules through the training period. Study drug is administered 3 times daily during daytime hours with one of these doses being 30 minutes prior to onset of ET sessions throughout the12 week trial. The objective is to determine if the oral sodium nitrite improves the clinical responses and tolerability of ET.

Phase:

Phase 2

Details

Lead Sponsor:

Barry Borlaug

Collaborators:

Aires Pharmaceuticals, Inc.
Mast Therapeutics, Inc.
National Heart, Lung, and Blood Institute (NHLBI)

Treatments:

Pharmaceutical Solutions